title: Open label study to evaluate the efficacy of re-treatment with etanercept in patients with psoriasis.
abstract: BACKGROUND
  Etanercept has been used to treat chronic plaque psoriasis. Previously reported data demonstrated that some patients experienced secondary failure and frequently rotational-switch therapy is used. The re-treatment with etanercept as part of the rotational therapy could be considered as another safe and efficient therapeutic approach.
  
  
  OBJECTIVE
  To evaluate the efficacy of the re-treatment with etanercept in patients with a history of etanercept use with good response and secondary loss of efficacy.
  
  
  METHODS
  This is an open label prospective study involving 20 patients with moderate to severe plaque psoriasis, who had been initially treated with etanercept and were re-treated after a variable interval with 50 mg BIW for 12 weeks.
  
  
  RESULTS
  At week 12 of etanercept re-treatment, 13 of 20 patients (65%) achieved a PGA score of 2 or less and 40% (8 of 20), achieved a PGA score of 0 to 1. Etanercept was well tolerated and no serious adverse events were reported.
  
  
  CONCLUSIONS
  Our study involved a small number of patients. Failure of etanercept was establish by patient's history. However we were able to correlate such failure from our medical records in 17 patients.
  
  
  CONCLUSIONS
  Re-treatment with etanercept, after secondary loss of efficacy should be considered in patients with psoriasis if satisfactory therapy cannot be achieved with other therapeutic regimens.
authors.affiliation: Florida Academic Dermatology Center, University of Miami Hospital, Miami, FL 33136, USA.
authors.forename: Adriana
authors.initials: A
authors.lastname: Abuchar
authors.forename: Magalys
authors.initials: M
authors.lastname: Vitiello
authors.forename: Carlos
authors.initials: C
authors.lastname: Ricotti
authors.forename: Annika
authors.initials: A
authors.lastname: Grant
authors.forename: Luis
authors.initials: L
authors.lastname: Dehesa
authors.forename: Francisco
authors.initials: F
authors.lastname: Kerdel
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept